NeuroOne Medical Technologies is a small medical device company focused on minimally invasive neurological devices for diagnosing and treating epilepsy and other neurological disorders. The company's core products are its Evo Cortical and Evo sEEG thin-film electrodes, which are temporarily placed on or within the brain to monitor and record electrical activity to help identify seizure-causing tissue, and the OneRF Brain Ablation System, the only FDA-cleared device that uses a single sEEG electrode for both diagnosis and therapeutic ablation. The OneRF system allows neurosurgeons to diagnose and treat in a single hospitalization at the patient's bedside, avoiding the cost of an operating room. All three products are distributed exclusively through Zimmer Biomet under an agreement running through 2034; Zimmer handles all commercialization and sales, while NeuroOne handles development, manufacturing, and regulatory matters. NeuroOne sells devices to Zimmer at a transfer price, making this a recurring consumables model driven by procedure volume at the approximately 200 Level 4 epilepsy centers in the U.S. Beyond its epilepsy franchise, NeuroOne is developing several pipeline products — including a trigeminal neuralgia ablation system, a drug-delivery sEEG electrode, a percutaneous spinal cord stimulation lead, and a basivertebral nerve ablation system — each targeting a new clinical application built on the existing thin-film electrode or OneRF platform. NeuroOne's strategy is consistent: develop and clear new applications via the FDA 510(k) pathway, then partner with established distributors rather than build its own commercial infrastructure.